Light (L) chains that edit anti-DNA heavy (H) chains rescue B-cell development by suppressing DNA binding. However, exceptional editor L chains allow B cells to reach splenic compartments even though their B-cell receptors remain autoreactive. Such incompletely edited B cells express multireactive antibodies that accumulate in the Golgi and are released as insoluble, amyloid-like immune complexes. Here, we examine examples of incomplete editing from the analysis of variable to joining (VJ) gene junction of the variable (Vλx) editor L chain. When paired with the anti-DNA heavy chain, V H 56R, the Vλx variants yield antibodies with differing specificities, including glycosaminoglycan reactivity. Our results implicate these specificities in the evasion of receptor editing through intracellular sequestration of IgM and the release of insoluble IgM complexes. Our findings can be extrapolated to human L chains and have implications for understanding a latent component of the Ig repertoire that could exert pathogenic and protective functions.
Light (L) chains that edit anti-DNA heavy (H) chains rescue B-cell development by suppressing DNA binding. However, exceptional editor L chains allow B cells to reach splenic compartments even though their B-cell receptors remain autoreactive. Such incompletely edited B cells express multireactive antibodies that accumulate in the Golgi and are released as insoluble, amyloid-like immune complexes. Here, we examine examples of incomplete editing from the analysis of variable to joining (VJ) gene junction of the variable (Vλx) editor L chain. When paired with the anti-DNA heavy chain, V H 56R, the Vλx variants yield antibodies with differing specificities, including glycosaminoglycan reactivity. Our results implicate these specificities in the evasion of receptor editing through intracellular sequestration of IgM and the release of insoluble IgM complexes. Our findings can be extrapolated to human L chains and have implications for understanding a latent component of the Ig repertoire that could exert pathogenic and protective functions. S elf-reactive B cells achieve tolerance by receptor editing, a process that replaces V H and/or V L genes encoding the autoreactive receptor with genes that change or modify the selfreactivity (1) . The process is stimulated by exposure to selfantigen (Ag) and is carried out by secondary rearrangement. The benefit of editing is that ongoing rearrangements can extinguish the autoreactive specificity. However, the immune system is neither perceptive nor perfect, and receptor editing also generates byproducts besides silenced anti-self receptors: The new receptors' affinity for self may decrease below the threshold that triggers self tolerance but could convert to full-blown autoreactivity by somatic mutation in the periphery (2) . Alternatively, editing can lead to rearrangements on a second allele, resulting in inclusion and the generation of bispecific, autoreactive B cells (2) (3) (4) (5) (6) . In such allelically included cells, the autoreactive receptor is "diluted out" by the nonautoreactive one (6, 7) , again resulting in the escape of an autoreactive B cell from self-tolerance.
We are particularly interested in editing that leads to receptors with modified self activities. Certain combinations of anti-DNA V H and editor V L chains yield multireactive-autoreactive B-cell receptors (BCRs). However, despite the self-reactivity of their BCRs, these B cells escape further regulation and enter the periphery (8-10). The combination of V H 56R anti-DNA heavy (H) and Vκ38c editor light (L) chains is a case in point. This autoreactive Ab accumulates in the Golgi, presumably by binding to specific glycosaminoglycans expressed inside the secretory pathway (11) . As a result, surface expression of the BCR is reduced, and B cells expressing V H 56R/Vκ38c escape from central tolerance.
B cells with incompletely edited anti-DNA receptors are a ready source of potentially pathogenic Abs because arginines (R) in V H function in an autonomous and additive manner as critical DNA binding residues (12) . Thus, DNA binding is achieved without regard to most L chains (13) . Most L chains sustain DNA binding when paired with V H 3H9 (14) or V H 56R (15) . A few, however, can function as effective editors of anti-DNA reactivity (16) . These anti-DNA editors are characterized by the presence of several aspartic acid (D) residues in their CDRs. The negatively charged Ds may block DNA binding by competing for the positive charges of Rs. The Vλx editor provides an example of just such an R-D interaction ( Fig. 1; ref. 17 ). Vλx differs from other editor Vs by having Ds in CDR2 (L2) and in CDR3 (L3) (18) . However, the high D content can be a liability: Vλx, presumably aided by the Ds, binds to cationic Ags such as MBP (Myelin Basic Protein) (19) . Importantly, if the Ds and Rs do not complement each other, the Ab may be only partially or incompletely edited. The receptor of an incompletely edited B cell may still bind DNA through free R(s), MBP by free D(s) and a variety of other Ags.
Many anti-DNA are multireactive as R residues in the CDRs can also contribute to binding to anionic phospholipids such as cardiolipin and phosphatidylserine (PS). Indeed, the original 3H9 antibody was found to bind not only to dsDNA and chromatin, but also to cardiolipin (20) . Site-directed mutagenesis experiments indicate that Rs in the H chain play a leading role in PS binding (21) , whereas the L chain modulates affinity, similar to anti-DNA (8) .
The mechanism of editing anti-DNAs, and some antibodies to anionic lipids, appears to depend on strategically positioned L chain Ds, such as D96 in Vλx. Here, we exploit a natural example of structural heterogeneity in Vλx that alters L3 conformation and D96 position. The V-J rearrangement process generates Vλx junctions (Fig. 2) that are shorter by two codons or longer by two codons relative to the exact, canonical junction (CJ; ref. 22 ). This junctional diversity accounts, in part, for the binding differences between V H 56R/Vλx monoclonal Abs (23) . Here, we compared Abs with the CJ of Vλx-Jλ2 to Abs with the two-codon insertion (+2) or deletion (−2). We studied the (self) Ag specificities of the three H/L pairs, and noted that the Abs differ in their binding to DNA, phospholipids and myosin. Of particular interest were differences in the binding of the Vλx variants to the Golgi and to glycosaminoglycans. We show that V H 56R/Vλx junctional variants that bind Golgi-associated Ags also accumulate inside cells, thereby recapitulating the result of V H 56R editing by the Vκ38c L chain (11) . The intracellular sequestration may obviate the need for editing of these anti-DNA receptors, as they are diverted to Ags expressed in the Golgi. The common result of editing by the Vλx variants and Vκ38c is highly significant. The repeated observation that the two hybridomas accumulate intracellular IgM and release insoluble IgM complexes suggests that insoluble, amyloid-like IgM deposits arise as a biologically relevant and predictable outcome of anti-DNA receptor editing.
Results
Binding of Recombinant scFv. We expressed single-chain variable region fragments (scFv) composed of V H 56R and each of three Vλx junctional variants (Fig. 2) in Escherichia coli to determine the contribution of Vλx-Jλ2 junctional diversity to Ab binding to DNA and PS. The CJ scFv bound DNA (Fig. 3A ) compared with an scFv in which the V H 56R was paired with Vκ12/13, an editor L chain that strongly inhibits DNA binding (11) . Relative to CJ scFv, the +2 scFv bound DNA about fivefold better, whereas the −2 scFv showed only background levels of DNA binding.
Some anti-DNA Abs such as the original 3H9 and its variants bind PS (8, 21) . Thus, we asked whether the three V H 56R/Vλx scFv bind PS. As control, we again used V H 56R/Vκ12/13 scFv, an H/L combination that binds PS. The CJ and +2 had comparable binding to PS, whereas −2 bound less well (Fig. 3B ). Because relative binding of −2 scFv to PS paralleled the binding to DNA, we infer that its combining site includes L3 and accommodates both Ags.
To assess the capacity of the scFvs for binding to protein Ags, we tested the binding to MBP, thyroglobulin, and myosin. The Vλx-Jλ2 junctional diversity had little to no effect on MBP binding, as each of the scFv bound comparably (Fig. 3C) . None of the scFv bound appreciably to thyroglobulin (Fig. 3D) , and only CJ bound myosin ( Fig. 3E and Table 1 ).
To explore binding to Golgi-associated Ags, we tested the V H 56R/Vλx scFv for binding to chondroitin, heparan sulfate and heparin, three complex cellular glycosaminoglycans. Only binding to heparin was observed, and only the +2 scFv bound strongly over a range of Ag concentrations (Fig. 3F) , thus resembling V H 56R/Vκ38c that, as previously noted, also binds heparin (24) .
IgM Distribution in Cells and Assembly of Polymeric IgM. Because of the parallel to V H 56R/Vκ38c, an IgM that accumulates in the Golgi (11), we tested the distribution of V H 56R/Vλx IgM in hybridoma cells. To examine if V H 56R/CJ Vλx associates with the Golgi, we stained cells with an antibody that binds giantin, a protein that resides in the Golgi membrane (25) . For sera from patients with autoimmune diseases such as systemic lupus erythematosus and Sjogren's syndrome, giantin is the most frequently recognized Golgi antigen (26) . Therefore, we used giantin as a marker for the Golgi and looked for colocalization with the Vλx variants.
We observed relatively little colocalization of CJ IgM and giantin ( Fig. 4A ) because this IgM was distributed more peripherally throughout the cytoplasm. In contrast, the −2 ( Fig. 4B ) and the +2 IgM (Fig. 4C ) accumulated in a more central location, and their binding showed considerable overlap with the binding of Abs to giantin. Because IgM rapidly transits through the Golgi, less than 5% of intracellular IgM is present at that location under steady-state conditions (24) . Notably, the −2 and +2 IgM, as V H 56R/Vκ38c in our earlier study (11) , showed notably increased accumulation in the Golgi.
A direct relationship between the Golgi accumulation of V H 56R/Vκ38c IgM and the release of insoluble IgM complexes from the cell has been reported (24) . Therefore, it was of interest to see whether any of the V H 56R/Vλx hybridomas also yielded IgM deposits. Strikingly, the +2 IgM recapitulated the ability of V H 56R/Vκ38c IgM to produce large extracellular IgM complexes (spherons, Fig. 4C ).
To further probe the mechanism of spheron production, we used metabolic labeling of proteins in V H 56R/Vλx CJ and +2 hybridomas (Fig. 4D ). For comparison, we labeled proteins in the V H 56R/Vκ38c hybridoma. The H and L chains associated into hemimers, monomers, and polymers with similar efficiencies in all three cell lines (compare lysate fractions). However, striking differences were noted among the extracellular forms of IgM. The CJ hybridoma predominantly secreted soluble IgM polymers, whereas the V H 56R/Vκ38c and +2 hybridomas secreted soluble hemimers and monomers but greatly reduced amounts of fully assembled IgM. Instead, polymeric IgM comprised the insoluble spheron fractions from the V H 56R/Vκ38c and +2 hybridomas. Thus, the intracellular assembly of Vκ38c and +2 IgM polymers results in a selective loss of solubility of the multivalent IgM species (Fig. 4D ). Multivalency could selectively favor the integration of IgM polymers into spherons if spheron formation reflects IgM binding to Golgi-associated, repetitive antigens. 2 . Sequences of the Vλx-Jλ2 junctions characterized in this study. Editor Vλx L chains use the canonical junction (Top, CJ) or junctions that represent a deletion of two codons (Middle, −2) or insertion of two codons (Bottom, +2) relative to the CJ. The figure shows the partial nucleotide sequences of the Vλx and Jλ2 gene segments and the three rearrangements along with the amino acid sequences encoded by the rearrangements. The alternative junctions were generated by deletion of seven nucleotides upstream of the TAA codon of Vλx or by the insertion of two codons between Vλx and Jλ2, with likely involvement of P nucleotides. The TAT codon at the Vλx-Jλ2 junction is residue 104 if residues are sequentially counted starting with the amino terminus of Vλx. In a survey of Vλx junctions, 24 of 24 junctions that were analyzed were generated by joining thymidine from Jλ2 to the first adenine of the TAA terminator, thus generating a tyrosine (TAT) codon at position 104 and preventing premature termination (44) .
Binding of scFv to Jurkat Cells and Glycosaminoglycan Arrays. To test whether Golgi accumulation of the −2 and +2 IgM reflects their antigen specificity, we assayed the binding of Vλx scFv to subcellular compartments in Jurkat cells (Fig. S1 ). Only the +2 scFv bound selectively to a centrally located compartment (Fig. S1C) ; its binding resembled the binding of MW1 (Fig. S1D) , one of a group of anti-poly Q mouse IgM that express Vλx and bind to the Golgi complex (17, 27) . The similarity between the +2 scFv and MW1 IgM binding suggested that the Vλx contributes to Golgi binding, even in the context of a different V H .
The accumulation of V H 56R/Vκ38c IgM in the Golgi and the formation of IgM spherons were correlated with a specific glycosaminoglycan binding profile (24) . Because the +2 and −2 IgM also accumulated in the Golgi and had similar Ag binding specificities as the V H 56R/Vκ38c, we sought to define the glycosaminoglycan specificity of the V H 56R/Vλx and V H 56R/Vκ38c scFv. We assayed the Abs for binding to microarray slides displaying 442 synthetic glycans (Fig. 5) . This analysis showed that the CJ scFv bound to GlcAβ1-3GlcNAcβ-Sp8 (spot #299), and the −2 scFv bound to a branched glycan structure consisting of two Lewis-A epitopes linked via mannose sugars to GlcNAc (spot # 350). The +2 V H 56R/Vλx and the V H 56R/Vκ38c scFv bound to both of these glycans (Fig. 5 C and D) . Thus, the specific glycosaminoglycan reactivities may explain the Golgi retention of IgM and the production of extracellular IgM deposits.
Comparison of Ab Structures. To visualize potential roles of Vλx junctional diversity in Ag binding, we compared the structures of three Abs using Vλx that have been determined by X-ray diffraction (17, 28, 29) . In each case, the structure of the unbound Abs and of the Ab-Ag complexes could be examined. Because all three Abs use the CJ Vλx, we avoided uncertainties associated with structural modeling. The Vλx participates in binding to a peptide from the Ebola virus (28), the parathyroid hormonerelated peptide (PHRP) (29) , and a poly-Q sequence (17) . Intriguingly, each of these diverse Ags follows a similar path across the combining site, which runs perpendicular to the Vλx L3 (Fig.  6A) . In each of the Ab-Ag complexes, the unusually long L3 of Vλx flexes toward and binds the Ag.
We use D96 to highlight contributions of Vλx L3 to Ag binding. The focused view is justified because D96 is frequently observed in editor L chains (16) . D96 may help to stabilize AbAg interactions. In Vλx, D96 has two important roles. First, D96 helps to organize the overall structure of the combining site by engaging T97 and V103 in L3 as well as Y31 in L1 (Fig. 6B) . Second, D96 participates in Ag binding. For example, in the MW1 complex with poly-Q, the D96 side chain pivots toward the Ag to H-bond with a glutamine (Fig. 6C) . Thus, D96 directly participates in Ag binding in MW1, as well as in the anti-PHRP and in the anti-Ebola Abs (Fig. 6D) . Interestingly, D96 is the only Vλx residue that contacts each of the three Ags.
The crystal structures of the Vλx Abs suggest how Vλx may edit DNA binding. Many anti-DNA H chains, V H 56R included, contain R within their H3 (13), and R96 in V H 56R participates in DNA binding (12) . MW1 also has R at position 96 of H3 and this R binds D60 in L2 (Fig. 1) . Likewise, D60 of Vλx may also H-bond with R96 in V H 56R, and, because R96 assists with DNA binding, D60 may interfere with DNA binding of V H 56R/Vλx. It is more difficult to predict how different lengths of L3 affect binding. The diverse lengths of Vλx-Jλ2 junctions surely yield alternative L3 conformations that could affect the structure of surrounding CDR or alter the interactions between H and L chains. One consequence of the −2 rearrangement is that D96 loses its L3 binding partner, because V103 is excluded from the −2 junction (Fig. 2) . Thus, D96 may be free to assume alternative conformations. Clearly, the −2 junction more effectively blocks the DNA binding of V H 56R. In contrast, extending L3 by two residues in the +2 junction may induce an alternative conformation that disrupts the interaction between R96 and D60 and allows both residues to more effectively orient toward distinct Ags.
Discussion
The junctional variants of Vλx demonstrate a variety of editing strategies: one type of junction vetoes autospecificity, a second type modifies specificity to promote multireactivity, and a third type does not affect autospecificity but instead broadens reactivity to include Ags that divert the BCR to an internal The Vλx junctional variants and Vκ38c were combined with V H 56R and compared as scFv for binding to DNA, PS, MBP, myosin, and heparin, as described in the text. Binding to synthetic glycosaminoglycans was tested on a glycan array, and intracellular IgM accumulation and spheron production were assessed by microscopy. A plus indicates binding, minus, no binding. compartment, thus limiting auto-Ag binding at the cell surface. L chain junctional alternatives provide a variety of nonconservative amino acids in the middle of the combining site (Fig. 2) , and variations at the junction generate new specificities ( Table 1 ). The importance of junctions is not unique to Vλx; different junctions of Vκ38c were shown to inhibit autoreactivity to differing degrees (9) , and junctions of Vκ20 to Jκ2 versus Jκ4 were shown to inhibit or sustain anti-nuclear autoreactivity (30) . The CJ junction of Vλx may provide R-D complementarity, but the alternative junctions may disrupt R-D interactions and yield R and D that are available for binding to multiple Ag. Multireactivity implies that multiple Ags compete for binding to the BCR and may thus effectively limit availability to the BCR at the cell surface, as is the case with allelic inclusion (4). Among the anti-DNA editors, Vλx has the highest content of Ds and the longest L3. A long and negatively charged L3 may be useful for reaching and suppressing the activity of different H chain Rs. In this sense, Vλx resembles VpreB, both in terms of its L3 length and abundance of negative charges (31) . The negative charges of VpreB L3 are also thought to bind to Rs in V H (31) and shield them from binding to Ag (32) .
The Vλx junctional variants provide a unique opportunity to examine the contributions of incomplete editing to auto-Ag binding (Fig. 3) . The −2 Vλx-Jλ2 junction inhibits DNA binding, reduces PS binding, and blocks heparin binding (Table 1) . Thus, the −2 Vλx-Jλ2 efficiently edits autospecificity. In contrast, the +2 editor Vλx is a poor inhibitor of autospecificity: it allows DNA, PS, MBP and heparin binding. The +2 scFv also binds the Golgi in Jurkat cells, and the +2 IgM accumulates in the Golgi of hybridomas (Fig. 4 and Fig. S1 ). The Golgi accumulation of IgM may be explained by the +2 scFv specificity for glycans (Fig. 5C) . Therefore, we surmise that the Golgi accumulation is caused by the binding of the +2 IgM to carbohydrate chains that are synthesized within that organelle. Interestingly, galectins, a family of cell surface proteins that bind carbohydrates, have binding sites that are enriched in R and D sidechains. These form extended π electron surfaces that stack bidentate and/or bifurcated ion pairs against the sugars (33) . Thus, it is reasonable to consider that R-D pairs that form as result of anti-DNA editing may directly participate in carbohydrate binding. Additional evidence for the binding of the V H 56R/+2 Vλx IgM to carbohydrates includes the formation and release of spherons.
The deposition of spherons, complexes that contain glycosaminoglycan-associated IgM (24), may initiate inflammation, tissue damage, and perhaps even amyloidosis. In this connection, it is intriguing that certain human L chains are associated with intracellular inclusions. For example, cytoplasmic Ab inclusions in 13 of 14 cases of lymphoproliferative disorder contained λ L chains (34) . In some of these cases, the cytoplasm contained inclusions that stained intensely for Ig. In at least one case, the Ig was found only inside the cell and not on the cell surface.
Is there a biological function for sequestered Abs or do they only emerge under conditions of immune dysregulation (35) ? The biological importance of Vλx is implicit in its conservation in vertebrate phylogeny. The conservation of Vλx is striking because its homology to other Vλs is no higher than to Vκs (36), hence, Vλx appears to have arisen at the time that κ and λ diverged. Also significant is the conservation of Vλx throughout the radiation of mammalian species, with human Vλ5-1 (37) and mouse Vλx orthologs sharing high D content, long L3, and a stop codon at the end of the V gene that requires an unusual rearrangement to yield a productive junction (38) . This conservation suggests a benefit of Vλx to the host. The benefit could be experimentally tested because incompletely edited Vλx Abs are present in the preimmune repertoire. They are also induced by nonspecific B-cell activators (LPS), reactive autoimmunity as induced by graft-versus-host disease, or injection of mercury chloride (GVHD, HgCl 2 ), and spontaneous autoimmunity (as in the mouse strain MRL). In addition, Vλx is elicited by immunization with a variety of foreign Ags like polyQ (27) and Ebola (39) . Glycan-reactive B cells also may have a protective role in human disease. It has been observed that glycan reactivity is a characteristic of broadly protective anti-HIV antibodies (40) . The specificity analysis of those antibodies identified a glycan structure that is similar to the branched glycan recognized by the V H 56R/+2 Vλx (Fig. 5) . Therefore, it will be of interest to further examine the regulation of B cells with glycan specificity.
These studies point to an effective vaccination strategy: To protect the population, a vaccine should be directed to B cells with receptors common to all or most of the population. These receptors must be made up of germ-line H and L chains to reach a sufficient frequency to guarantee Ag interaction with a B-cell (41) . Such inherited combinations provide an immediate response to bacterial carbohydrates. Germ-line Abs initiate the primary response to a variety of Ags, as originally shown for the immune response to dextran (42) and to influenza HA (43) . As Bound scFv were detected by AF488 labeled rabbit IgG. The relative fluorescence units from six replicates were averaged and plotted. The Vλx-Jλ2 CJ (A) bound preferentially to GlcAβ1-3GlcNAcβ-Sp8 (spot #299), −2 V H 56R/Vλx (B) bound strongly to two Lewis-A epitopes linked via mannose sugars to GlcNAc (spot # 350), whereas the +2 V H 56R/Vλx (C) and the V H 56R/Vκ38c (D) had a mixed preference for the two glycans. result of editing, nonrandom V H /V L combinations can attain high frequencies. These combinations include incompletely edited B cells that escape tolerance by sequestration and accumulate in the periphery. Such B cells could be exploited for the purpose of a broadly effective vaccine.
Materials and Methods
Cell Culture and Metabolic Labeling. The B-cell hybridomas expressing junctional variants of V H 56R/Vλx and V H 56R/Vκ38c IgM were described (11) . For microscopy and metabolic labeling, cells were grown as reported (24) .
Single-Chain Fv Expression and Binding Assays. The scFv expression vectors and methods for the purification of bivalent scFv proteins were described (11) . The −2 and +2 expression vectors were constructed using oligonucleotides that exactly matched the Vλx-Jλ2 junctions expressed in the B-cell hybridomas (Fig. 2) . The binding to DNA, PS, MBP, thyroglobulin, and myosin was assessed by direct immunoassay. Binding to heparin was measured by capturing heparin on a Hybond nylon membrane, blocking the membrane, and assaying scFv binding by rabbit IgG-HRP conjugate. Signals were detected by chemiluminescence and quantified with the Adobe Photoshop histogram function. Immunofluorescence and confocal microscopy were performed as described (11, 24) .
Glycan Microarray. Binding to glycan microarrays was performed by the Core H component of the consortium for functional glycomics at Emory University (Atlanta, GA), Department of Biochemistry under the direction of David F. Smith. The fluorescence data were acquired using a PerkinElmer Scan Array scanner. The data were analyzed using Microsoft Excel.
Molecular Structure Analysis. All structures were available from previously published reports and were examined using the PyMOL Molecular Graphics System, Version 0.99rc2 (Schrödinger).
